Entering text into the input field will update the search result below

Antares Pharma's (ATRS) CEO Bob Apple on Q4 2020 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Antares Pharma, Inc. (ATRS) Q4 2020 Earnings Conference Call March 2, 2021 8:30 AM ET

Company Participants

Tram Bui - VP, Corporate Communications & IR

Bob Apple - President & CEO

Fred Powell - EVP & CFO

Pat Shea - SVP, Commercial

Conference Call Participants

Briana Warschun - Jefferies

David Amsellem - Piper Sandler

Elliot Wilbur - Raymond James

Gregg Gilbert - Truist Securities

Raymond Wu - Ladenburg Thalmann


Ladies and gentlemen, welcome to the Antares Pharma Fourth Quarter and Full-Year 2020 Financial and Operating Results Conference Call. Throughout today's recorded presentation, all participants will be in listen-only mode. After the presentation, there will be an opportunity to ask questions. [Operator Instructions].

I will now hand the conference over to Tram Bui, Antares' Vice President and Corporate Communications and Investor Relations.

Tram Bui

Thank you, operator, and good morning, everyone.

Earlier today, we announced our fourth quarter and full-year 2020 financial results and operating achievements. A copy of the press release and slide presentation for today's conference call are available in the Investor Relations section of the Antares Pharma corporate website.

Before we begin, I'd like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Examples of forward-looking statements include those related to our future financial and operating results, including our expectations regarding the impact of the ongoing COVID-19 pandemic and mitigation measures implemented in response to the outbreak, on our overall business, operating results and financial condition, our ability to achieve the 2021 revenue guidance, future revenue growth, prescription volumes, and market share for our products and our partners' products including XYOSTED, NOCDURNA, and Teva's generic EpiPen, FDA actions and other regulatory activities including actions with respect to Makena and approval of Teva's

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.